



# Melanoma Pathology Working Group Meeting for European Dermatopathologists and Pathologists

**Charité Berlin**  
**October 15, 2015**

**Local Host: Prof. Dr. Manfred Dietel, Pathology Institute, Charité**

Course Moderators:

**Daniela Massi, M.D.**

Associate Professor of Pathology  
Division of Pathological Anatomy  
University of Florence  
Florence, Italy

**Susana Puig, M.D.**

Director of the Research Program  
Melanoma Unit at the University Hospital  
Clinic of Barcelona  
Barcelona, Spain

**Course Location:**

Pathology Institute, Charité Campus Mitte, Virchowweg 15, Berlin, Germany.



No Fee to Attend.

European CME credits by the EACCME (European Accreditation Council for Continuing Medical Education) will be requested.

If you wish to attend, please register (**before October 8<sup>th</sup> 2015**) through our website: [www.melanomagroup.eu](http://www.melanomagroup.eu)

In case of questions, please e-mail to: [cccc@charite.de](mailto:cccc@charite.de)

## **Scientific Programme**

### **Teaching Course**

#### **Integrated approach to challenging melanocytic lesions: Clinico-dermoscopic/confocal-pathological correlations**

This course is designed for pathologists and dermatopathologists and its goal is to impart an integrated approach to the diagnosis of challenging melanocytic lesions. Identified topics reflect a subset of the most common diagnostic dilemmas and misdiagnoses seen in dermatopathology consultative practice.

Dermoscopy has demonstrated a clear positive impact in the early detection of malignant melanoma and the course will focus on the description of the dermoscopically melanoma subtypes in parallel with discussion of histopathological correlates and molecular features by a panel of dermatopathologists. In addition, the added value of confocal microscopy and will have its relevant place.

The course will be presented in a case-based format. Pre-registrants will be able to view virtual slides, case histories, clinical/dermoscopic images prior to the meeting.

- 14.00-14.15 Case 1 Special location (face) (J. Malvehy – D. Massi)
- 14.15-14.30 Case 2 Special location (acral) (S. Puig - D. Massi)
- 14.30-14.45 Case 3 Special location (mucosal) (S. Puig - S. Koljenovic)
- 14.45-15.00 Case 4 Difficult case (S. Puig – S. Koljenovic)
- 15.00-15.15 Case 5 Difficult case (J. Malvehy – W. Blokx)
- 15.15-15.30 Case 6 Difficult case (J. Malvehy – W. Blokx)
- 15.30-15.45 Case 7 Difficult case (J. Malvehy – L. Alos)
- 15.45-16.00 Case 8 Difficult case (S. Puig – L. Alos)
- 16.00-16.15 Case 9 Spitzoid lesion (S. Puig – M. Mihm)
- 16.15-16.30 Case 10 Difficult case (J. Malvehy – M. Mihm)

16.30-17.00 Discussion

### **Lecture**

#### **17.00-17.30**

Molecular testing by next-generation sequencing in advanced melanoma  
Korinna Jöhrens, Berlin

**Speakers:**

Llucia Alos, Barcelona, Spain  
Willeke Blokk, Nijmegen, The Netherlands  
Korinna Jöhrens, Berlin, Germany  
Senada Koljenovic, Rotterdam, The Netherlands  
Joseph Malvey, Barcelona, Spain  
Daniela Massi, Florence, Italy  
Martin C. Mihm, Boston, USA  
Susana Puig, Barcelona, Spain

**Welcome Message from the Chairman of the EORTC Melanoma Pathology Group**

The EORTC Melanoma Pathology Group has the primary goal of promoting collaborative and interdisciplinary activities, research and education in the field of melanoma pathology. In addition, the role of pathologists inside the EORTC Melanoma Group is to support clinical trials and their research aspects by offering quality control as well as to initiate basic science studies or new experimental basic projects that have relevance to the overall understanding of melanogenesis and melanocyte biology.

The Group represents a friendly and informal environment, favouring communication and an unrestrained exchange of scientific information beyond state boundaries.

Starting from 2015, it has been agreed that in association with the annual EORTC Melanoma Group meetings <http://www.melanomagroup.eu/site/> there will be a special session with teaching courses for pathologists focused on different topics ranging from problematic diagnostic areas in melanoma to molecular characterization and novel tissue biomarkers discovery in the era of the novel melanoma therapies.

It is critical that we all participate actively in these activities to develop a system that is beneficial to our patients and applicable to our practicing physicians, enhanced by our experience and direction.

Unfortunately, due to a conflict of commitments I am unable to attend this first session of pathology centred teaching and discussion but I know it is in very expert hands and am confident it will be the first of a regular component of the EORTC meeting.



Prof. Martin Cook  
Chairman  
EORTC Melanoma Pathology Group